Astal Lab

how big is Astal Lab?

As of Jun 06, Astal Laboratories Ltd has a market capitalization of 148.00 Cr, with recent net sales of 64.24 Cr and net profit of 8.92 Cr over the last four quarters. Shareholder's funds are valued at 23.34 Cr, and total assets amount to 36.61 Cr as of Mar'24.

Market Cap: As of Jun 06, Astal Laboratories Ltd has a market capitalization of 148.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters, which includes Mar'25, Dec'24, Sep'24, and Jun'24, is 64.24 Cr. The sum of Net Profit for the same period is 8.92 Cr. This data is presented on a Standalone basis.<BR><BR>Balance Sheet Snapshot: This is Standalone data for the reporting period of Mar'24. The Shareholder's Funds are valued at 23.34 Cr, and the Total Assets amount to 36.61 Cr.

Who are in the management team of Astal Lab?

As of March 2018, the management team of Astal Lab includes Sudhir Kumar Parasrampuria as Chairman and Managing Director, along with Gautam Lhila, Manoj Kumar Poddar, and Parwati Parasrampuria in non-executive roles.

As of March 2018, the management team of Astal Lab includes:<BR><BR>1. Sudhir Kumar Parasrampuria - Chairman and Managing Director<BR>2. Gautam Lhila - Non Executive Independent Director<BR>3. Manoj Kumar Poddar - Non Executive Independent Director<BR>4. Parwati Parasrampuria - Non Executive Director<BR><BR>Sudhir Kumar Parasrampuria serves as the Chairman and Managing Director, while the other members hold non-executive positions.

What does Astal Lab do?

Astal Laboratories Ltd, a Micro Cap company established in 1993, operates in the Trading & Distributors industry, reporting net sales of 23 Cr and a net profit of 3 Cr for March 2025. Key metrics include a P/E of 16.00 and a market cap of Rs 148 Cr.

Overview: <BR>Astal Laboratories Ltd operates in the Trading & Distributors industry and is classified as a Micro Cap company.<BR><BR>History: <BR>The company was incorporated in August 1993 and was formerly known as Macro (International) Exports Limited. The latest quarterly results reported net sales and net profit for March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 23 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 3 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 148 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 16.00 <BR>Industry P/E: 30 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.12 <BR>Return on Equity: 30.26% <BR>Price to Book: 4.98<BR><BR>Contact Details: <BR>Address: 24/147 Ground Floor, Plaza Kalpana Birhana Road Kanpur Uttar Pradesh : 208001 <BR>Tel: 91-512-2332481 <BR>Email: miel1@rediffmail.com <BR>Website: http://www.miel.co.in

Has Astal Lab declared dividend?

No Dividend History Available

Who are the peers of the Astal Lab?

Astal Lab's peers include MMTC, Lloyds Enterpris, PTC India, Optiemus Infra, Kemp & Co., Zenith Exports, Prithvi Exchange, Maximus Interna., and MRP Agro. Astal Lab has a 1-year return of 110.35%, outperforming all peers, while Lloyds Enterpris leads with a 31.89% return.

Peers: The peers of Astal Lab are MMTC, Lloyds Enterpris, PTC India, Optiemus Infra, Kemp & Co., Zenith Exports, Prithvi Exchange, Maximus Interna., and MRP Agro.<BR><BR>Quality Snapshot: Excellent management risk is observed at Lloyds Enterpris, Prithvi Exchange, Maximus Interna., and MRP Agro, while Good management risk is found at PTC India, and the rest. Average management risk is present at Lloyds Enterpris, while Below Average management risk is seen at MMTC, Optiemus Infra, Kemp & Co., Zenith Exports, and Astal Lab. In terms of growth, Excellent growth is noted at Lloyds Enterpris and Prithvi Exchange, while Good growth is found at Optiemus Infra, Maximus Interna., and MRP Agro, and the rest. Below Average growth is observed at MMTC, PTC India, Kemp & Co., Zenith Exports, and Astal Lab. For capital structure, Excellent capital structure is seen at Lloyds Enterpris and Prithvi Exchange, while Good capital structure is noted at Maximus Interna. Below Average capital structure is present at MMTC, PTC India, Optiemus Infra, Kemp & Co., Zenith Exports, and Astal Lab.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Lloyds Enterpris at 31.89%, while the peer with the lowest is Maximus Interna. at -44.88%. Astal Lab's own 1-year return is 110.35%, which is significantly higher than all peers. Additionally, the six-month return is negative for MMTC, Optiemus Infra, Maximus Interna., and Zenith Exports.

What is the technical trend for Astal Lab?

As of May 27, 2025, Astal Lab's technical trend is mildly bearish, with bearish signals from the weekly MACD and daily moving averages, although the weekly KST shows mild bullishness and Bollinger Bands indicate potential volatility.

As of 27 May 2025, the technical trend for Astal Lab has changed from bearish to mildly bearish. The weekly MACD remains bearish, while the monthly MACD is mildly bearish, indicating a lack of strong upward momentum. The RSI on a monthly basis is bearish, suggesting weakness in price action. Daily moving averages are bearish, reinforcing the negative sentiment. However, the KST on a weekly basis is mildly bullish, which introduces some mixed signals. Bollinger Bands show a sideways trend weekly but are mildly bullish monthly, indicating potential for volatility. Overall, the current stance is mildly bearish with weak momentum, driven primarily by the bearish indicators in MACD and moving averages.

Who are the top shareholders of the Astal Lab?

The top shareholders of Astal Lab are Aceso Research Labs LLP with 19.93%, followed by Radha Krishna Doradla at 3.56%. Individual investors collectively own 73.8%, with no institutional holdings or pledged promoter shares.

The top shareholders of Astal Lab include Aceso Research Labs LLP, which holds the largest stake at 19.93%. Following that, the highest public shareholder is Radha Krishna Doradla, with a 3.56% share. Additionally, individual investors collectively hold a significant portion of the company at 73.8%. There are no institutional holdings from mutual funds or foreign institutional investors, and there are no pledged promoter holdings.

How has been the historical performance of Astal Lab?

Astal Lab experienced significant growth from March 2023 to March 2025, with net sales rising from 3.43 Cr to 64.23 Cr and profit after tax increasing from 0.02 Cr to 8.93 Cr. However, cash flow from operating activities remained negative at -12.00 Cr in March 2025.

Answer:<BR>The historical performance of Astal Lab shows significant growth in net sales and profitability over the years, particularly from March 2023 to March 2025.<BR><BR>Breakdown:<BR>Astal Lab's net sales increased dramatically from 3.43 Cr in March 2023 to 64.23 Cr in March 2025, marking a substantial growth trajectory. The total operating income followed a similar trend, rising from 3.43 Cr in March 2023 to 64.23 Cr in March 2025. The company's total expenditure also increased, but at a slower pace, reaching 51.46 Cr in March 2025 from 3.56 Cr in March 2023. This led to an operating profit (PBDIT) of 12.90 Cr in March 2025, a significant improvement from a loss of 0.13 Cr in March 2023. Consequently, profit before tax surged to 11.98 Cr in March 2025, compared to just 0.03 Cr in March 2023, resulting in a profit after tax of 8.93 Cr in March 2025, up from 0.02 Cr in March 2023. The company's total assets grew to 63.34 Cr in March 2025 from 9.91 Cr in March 2023, while total liabilities increased to 63.34 Cr from 9.91 Cr in the same period. However, cash flow from operating activities remained negative, at -12.00 Cr in March 2025, indicating challenges in cash management despite the growth in sales and profits.

Is Astal Lab overvalued or undervalued?

As of December 3, 2025, Astal Lab is considered a very attractive investment due to its undervalued status, highlighted by a PE ratio of 9.14, a PEG ratio of 0.10, and a strong ROCE of 27.45%, despite recent underperformance compared to the Sensex, while its long-term returns significantly exceed those of the index.

As of 3 December 2025, the valuation grade for Astal Lab has moved from attractive to very attractive, indicating a positive shift in its perceived value. The company is currently deemed undervalued, supported by a PE ratio of 9.14, an EV to EBIT of 6.96, and an impressive ROCE of 27.45%. In comparison to peers, PTC India, which is also rated very attractive, has a lower PE ratio of 7.21, while Elitecon International is categorized as very expensive with a PE ratio of 197.75, highlighting Astal Lab's relative affordability.<BR><BR>Astal Lab's valuation metrics, particularly its PEG ratio of 0.10, suggest significant growth potential compared to its price, further reinforcing the undervaluation narrative. Despite recent underperformance relative to the Sensex over the past month and year, the long-term outlook remains strong, with a remarkable 10-year return of 281.82%, significantly outpacing the Sensex's 228.77%. This combination of robust financial ratios and favorable peer comparisons positions Astal Lab as a compelling investment opportunity.

When is the next results date for Astal Laboratories Ltd?

The next results date for Astal Laboratories Ltd is 30 May 2026.

The next results date for Astal Laboratories Ltd is scheduled for 30 May 2026.

Should I buy, sell or hold Astal Laboratories Ltd?

Are Astal Laboratories Ltd latest results good or bad?

Astal Laboratories Ltd's latest results show strong revenue growth and a significant increase in net profit, but concerns arise from sharply declining profit margins and negative operating cash flow, indicating challenges in profitability and cash management. Overall, the results reflect good growth potential but raise red flags for investors.

Astal Laboratories Ltd's latest results present a mixed picture. On one hand, the company achieved a remarkable net profit of ₹7.68 crores in Q4 FY26, which is a significant increase of 225.42% compared to the previous quarter. Additionally, revenue surged by 156.60% quarter-on-quarter to ₹134.05 crores, indicating strong topline growth.<BR><BR>However, there are notable concerns regarding profitability. The operating margin has contracted sharply from 17.81% in the same quarter last year to just 7.60%, and the profit after tax (PAT) margin has halved from 11.67% to 5.73%. This suggests that while the company is growing its revenue, it is facing challenges in maintaining profitability, possibly due to rising costs or pricing pressures.<BR><BR>Furthermore, the company's cash flow situation raises red flags, as it reported negative operating cash flow of ₹12.00 crores for FY25, indicating that profits are not translating into cash. This disconnect could limit financial flexibility moving forward.<BR><BR>In summary, while Astal Laboratories has demonstrated impressive revenue growth and improved net profit, the significant margin compression and negative cash flow present serious challenges that investors should consider. Overall, the results can be seen as good in terms of growth but concerning regarding profitability and cash flow management.

Why is Astal Laboratories Ltd falling/rising?

As of 02-Jun, Astal Laboratories Ltd's stock price is at 68.19, reflecting a 4.58% decrease and significant underperformance over the past week and year-to-date. The stock is trading below its moving averages, indicating a bearish trend despite increased investor participation.

As of 02-Jun, Astal Laboratories Ltd's stock price is falling, currently at 68.19, which reflects a decrease of 3.27 or 4.58%. The stock has been underperforming significantly, with a consecutive decline over the last three days, resulting in a total drop of 7.17% during this period. Although the stock opened today with a gain of 2.16% and reached an intraday high of Rs 73, it quickly fell to a low of Rs 68, indicating volatility and a lack of sustained upward momentum.<BR><BR>In terms of performance relative to the market, Astal Laboratories has underperformed its sector by 4.76% today. Over the past week, the stock has declined by 6.88%, while the benchmark Sensex has only fallen by 1.79%. Year-to-date, the stock is down 21.49%, compared to a 12.40% decline in the Sensex, highlighting a significant lag behind the broader market.<BR><BR>Additionally, the stock is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which typically indicates a bearish trend. Despite a rise in investor participation, with a notable increase in delivery volume, the overall sentiment appears negative, contributing to the stock's decline.

Which are the latest news on Astal Lab?